Shots:
- Earendil Labs has dosed the first patient with HXN-1001 in the P-IIa trial, & completed enrolment of healthy subjects in the P-I trial across Australia
- The P-IIa trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of HXN-1001 vs PBO in ulcerative colitis patients
- HXN-1001 is a half-life extended anti-TL1A antibody showing superior efficacy vs benchmark assets in preclinical in vitro & animal models, with prolonged in vivo half-life & high-concentration formulation enabling SC administration
Ref: PRnewswire | Image: Earendil Labs |Press Release
Related News: Earendil Labs and Sanofi Forge ~$2.56B Deal to Advance Bispecific Antibodies for Autoimmune Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
